{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:50:04Z","timestamp":1761238204747,"version":"3.41.0"},"reference-count":50,"publisher":"Cambridge University Press (CUP)","issue":"4","license":[{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["www.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Acta Neuropsychiatr."],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:sec id=\"S0924270815000149_abs1\" sec-type=\"general\"><jats:title>Objective<\/jats:title><jats:p>The<jats:italic>N<\/jats:italic>-methyl-<jats:sc>d<\/jats:sc>-aspartate receptor (NMDAR) antagonist ketamine, produces rapid and enduring antidepressant effect in patients with treatment-resistant depression. Similar dramatic effects have not been observed in clinical trials with other NMDAR antagonists indicating ketamine may possess unique pharmacological properties. Tetrabenazine induces ptosis (a drooping of the eyelids), and the reversal of this effect, attributed to a sympathomimetic action, has been used to detect first-generation antidepressants, as well as ketamine. Because the actions of other NMDAR antagonists have not been reported in this measure, we examined whether reversal of tetrabenazine-induced ptosis was unique to ketamine, or a class effect of NMDAR antagonists.<\/jats:p><\/jats:sec><jats:sec id=\"S0924270815000149_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>The effects of ketamine and other NMDAR antagonists to reverse tetrabenazine-induced ptosis were examined and compared with their antidepressant-like effects in the tail suspension test (TST) in mice.<\/jats:p><\/jats:sec><jats:sec id=\"S0924270815000149_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>All the NMDAR antagonists tested produced a partial reversal of tetrabenazine-induced ptosis and, as expected, reduced immobility in the TST. Ketamine, memantine, MK-801 and AZD6765 were all about half as potent in reversing tetrabenazine-induced ptosis compared to reducing immobility in the TST, while an NR2B antagonist (Ro 25-6981) and a glycine partial agonist (ACPC) were equipotent in both tests.<\/jats:p><\/jats:sec><jats:sec id=\"S0924270815000149_abs4\" sec-type=\"conclusion\"><jats:title>Conclusion<\/jats:title><jats:p>The ability to reverse tetrabenazine-induced ptosis is a class effect of NMDAR antagonists. These findings are consistent with the hypothesis that the inability of memantine, AZD6765 (lanicemine) and MK-0657 to reproduce the rapid and robust antidepressant effects of ketamine in the clinic result from insufficient dosing rather than a difference in mechanism of action among these NMDAR antagonists.<\/jats:p><\/jats:sec>","DOI":"10.1017\/neu.2015.14","type":"journal-article","created":{"date-parts":[[2015,7,3]],"date-time":"2015-07-03T15:42:34Z","timestamp":1435938154000},"page":"228-234","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":14,"title":["Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test"],"prefix":"10.1017","volume":"27","author":[{"given":"Phil","family":"Skolnick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Kos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Czekaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Popik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2015,4,10]]},"reference":[{"key":"S0924270815000149_ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2010.12.015"},{"key":"S0924270815000149_ref40","unstructured":"Forest Laboratories. NAMENDA (memantine hydrochloride) PDR, 2013. Available at http:\/\/www.frx.com\/pi\/namenda_pi.pdf, accessed on March 2015."},{"key":"S0924270815000149_ref4","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.1.153"},{"key":"S0924270815000149_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2013.01.021"},{"key":"S0924270815000149_ref45","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009336735"},{"key":"S0924270815000149_ref43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1993.tb01351.x"},{"key":"S0924270815000149_ref49","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91888-2"},{"key":"S0924270815000149_ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-008-1158-z"},{"key":"S0924270815000149_ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-008-0128-2"},{"key":"S0924270815000149_ref3","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0022-3565(24)37943-1","article-title":"Differences in degree of trapping of low-affinity uncompetitive N-methyl-d-aspartic acid receptor antagonists with similar kinetics of block","volume":"288","author":"Mealing","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"S0924270815000149_ref35","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-196709000-00008"},{"key":"S0924270815000149_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.10.001"},{"key":"S0924270815000149_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2011.05.010"},{"key":"S0924270815000149_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.06.028"},{"key":"S0924270815000149_ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.05.028"},{"key":"S0924270815000149_ref28","doi-asserted-by":"publisher","DOI":"10.1038\/nature10130"},{"key":"S0924270815000149_ref46","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.13101434"},{"key":"S0924270815000149_ref11","doi-asserted-by":"publisher","DOI":"10.1007\/BF00176837"},{"key":"S0924270815000149_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(85)90128-5"},{"key":"S0924270815000149_ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.02.017"},{"key":"S0924270815000149_ref44","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(99)00019-2"},{"key":"S0924270815000149_ref19","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200006260-00008"},{"key":"S0924270815000149_ref6","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2013.130"},{"key":"S0924270815000149_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.10.019"},{"key":"S0924270815000149_ref8","doi-asserted-by":"publisher","DOI":"10.1038\/266730a0"},{"key":"S0924270815000149_ref9","doi-asserted-by":"publisher","DOI":"10.1007\/BF00428203"},{"key":"S0924270815000149_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2005.03.008"},{"key":"S0924270815000149_ref13","first-page":"68","article-title":"Evaluation of ketamine HCl for anti-depressant activity","volume":"214","author":"Sofia","year":"1975","journal-title":"Arch Inter Pharmacodyn Ther"},{"key":"S0924270815000149_ref14","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-197309000-00003"},{"key":"S0924270815000149_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(87)90002-9"},{"key":"S0924270815000149_ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-011-2169-8"},{"key":"S0924270815000149_ref18","doi-asserted-by":"publisher","DOI":"10.1097\/00008877-200505000-00004"},{"key":"S0924270815000149_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2011.06.015"},{"key":"S0924270815000149_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2007.02.019"},{"key":"S0924270815000149_ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-013-1281-9"},{"key":"S0924270815000149_ref39","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.13.6.759"},{"key":"S0924270815000149_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2013.02.015"},{"key":"S0924270815000149_ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.08.015"},{"key":"S0924270815000149_ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S1734-1140(13)71080-6"},{"key":"S0924270815000149_ref32","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)90516-9"},{"key":"S0924270815000149_ref48","first-page":"405","article-title":"MK-801 for epilepsy: a pilot study","volume":"38","author":"Leppik","year":"1988","journal-title":"Neurology"},{"key":"S0924270815000149_ref34","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31825d70d6"},{"key":"S0924270815000149_ref36","doi-asserted-by":"publisher","DOI":"10.1007\/BF00427414"},{"key":"S0924270815000149_ref37","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430020204"},{"key":"S0924270815000149_ref38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.18.7104"},{"key":"S0924270815000149_ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-012-9281-2"},{"key":"S0924270815000149_ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(02)00055-2"},{"key":"S0924270815000149_ref47","first-page":"1","article-title":"A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes","author":"Mcgirr","year":"2014","journal-title":"Psychol Med"},{"key":"S0924270815000149_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(91)90894-V"},{"key":"S0924270815000149_ref1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.244"}],"container-title":["Acta Neuropsychiatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924270815000149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:36:58Z","timestamp":1748479018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924270815000149\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,10]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0924270815000149"],"URL":"https:\/\/doi.org\/10.1017\/neu.2015.14","relation":{},"ISSN":["0924-2708","1601-5215"],"issn-type":[{"type":"print","value":"0924-2708"},{"type":"electronic","value":"1601-5215"}],"subject":[],"published":{"date-parts":[[2015,4,10]]},"assertion":[{"value":"\u00a9 Scandinavian College of Neuropsychopharmacology 2015\u00a0","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}